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Introduction
The infiltration of monocytes and T cells into the kidney
mediates tissue injury (1). During renal injury, infiltrat-
ing cells accumulate in glomeruli and in the interstitium,
where their interaction with resident kidney cells, includ-
ing tubular epithelial cells (TEC), stimulates the infil-
trating and resident cells to generate molecules that pro-
mote kidney injury. Consequently, the accumulation of
monocytes and T cells, and the ensuing inflammation,
gives rise to glomerulosclerosis, crescent formation,
tubular atrophy, interstitial fibrosis, and progressive
renal failure. The infiltration of monocytes and T cells
into the kidney is dependent on chemokines released by
injured resident kidney cells (1, 2). These chemokines
belong to a “superfamily” of small chemoattractant pro-
teins that promote the recruitment and activation of
infiltrating cells (3). During inflammation, the sustained
release of chemokines by injured cells results in an
increasing concentration gradient that is maximal with-
in damaged tissue and is responsible for the unidirec-
tional movement of infiltrating cells (2). Because
chemokines are not crucial for most normal tissue func-
tions (4, 5), and are induced during inflammation, they
are attractive targets for therapeutic intervention for a
broad array of diseases. In this group of chemokines,
attention has focused on monocyte chemoattractant
protein-1 (MCP-1) because it is a potent chemoattrac-
tant of monocytes, T cells, and natural killer cells (6–8).
Consequently, blocking MCP-1 offers therapeutic possi-
bilities in kidney diseases dependent on T-cell and/or
monocyte–mediated injury, including IgA nephropathy,
lupus nephritis, membranoproliferative glomerulone-
phritis , rapid progressive glomerulonephritis, and tubu-
lointerstitial nephritis (9–12).
MCP-1 may be responsible for inducing kidney tubular
and/or glomerular damage. Renal parenchymal cells
(RPC), most notably mesangial cells and TEC, are known
to produce MCP-1 in response to interleukin-1, tumor
necrosis factor-a , interferon-g , and circulating IgG com-
plexes (13–16). TEC and mesangial cells express MCP-1
during human and experimental kidney diseases (9, 12,
17–22). Experimental studies have linked MCP-1 expres-
sion in glomeruli with an influx of macrophages using
anti-thymocyte serum (16). Similarly, MCP-1 expression by
TEC is noted to increase the number of macrophages in
renal ischemia, ureteral obstruction, and protein overload
(17–19). Because MCP-1 is among a vast array of molecules
induced in glomeruli and TEC during inflammation (2), it
is uncertain whether this chemokine contributes to
glomerular and/or tubulointerstitial inflammation.
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Monocyte chemoattractant protein-1 (MCP-1) is upregulated in renal parenchymal cells during kidney
disease. To investigate whether MCP-1 promotes tubular and/or glomerular injury, we induced nephro-
toxic serum nephritis (NSN) in MCP-1 genetically deficient mice. Mice were analyzed when tubules and
glomeruli were severely damaged in the MCP-1–intact strain (day 7). MCP-1 transcripts increased five-
fold in MCP-1–intact mice. MCP-1 was predominantly localized within cortical tubules (90%), and most
cortical tubules were damaged, whereas few glomerular cells expressed MCP-1 (10%). By comparison,
there was a marked reduction (>40%) in tubular injury in MCP-1–deficient mice (histopathology, apop-
tosis). MCP-1–deficient mice were not protected from glomerular injury (histopathology, proteinuria,
macrophage influx). Macrophage accumulation increased adjacent to tubules in MCP-1–intact mice
compared with MCP-1–deficient mice (70%, P < 0.005), indicating that macrophages recruited by MCP-
1 induce tubular epithelial cell (TEC) damage. Lipopolysaccharide-activated bone marrow macrophages
released molecules that induced TEC death that was not dependent on MCP-1 expression by
macrophages or TEC. In conclusion, MCP-1 is predominantly expressed by TEC and not glomeruli, pro-
motes TEC and not glomerular damage, and increases activated macrophages adjacent to TEC that dam-
age TEC during NSN. Therefore, we suggest that blockage of TEC MCP-1 expression is a therapeutic
strategy for some forms of kidney disease.
J. Clin. Invest. 103:73–80 (1999).
Gene knockout strains deficient in MCP-1 or its
receptor, CCR2, have established the requirement for
MCP-1 in inflammation. MCP-1 and CCR2–deficient
mice have a reduction in macrophage recruitment and
inflammation in thioglycolate-elicited peritonitis,
delayed-type hypersensitivity, and pulmonary granulo-
mas compared with their wild-type counterparts (5,
23–25). Therefore, MCP-1 contributes to inflamma-
tion, but it is uncertain whether it is limited to select
tissues and recruits specific macrophages.
In this study, we tested the hypothesis that MCP-1 is
responsible for glomerular and/or tubular kidney injury.
To evaluate this hypothesis, we (a) induced glomerular
and tubular injury in MCP-1–intact and –deficient mice
using nephrotoxic serum, an experimental model con-
sisting of an influx of monocytes and T cells resulting in
glomerular and tubular injury, and (b) identified the
intrarenal pathogenic mechanisms dependent on MCP-1.
Methods
Mice. MCP-1–intact and –deficient B6/129 mice (129SV/J ·
C57BL/6)F1 (provided by B.J. Rollins, Dana Farber Cancer
Institute, Boston, Massachusetts, USA) were maintained in a
pathogen-free animal facility. MCP-1–deficient mice were
created by targeted gene disruption (5). Control MCP-
1–intact mice were derived from matings of mice heterozy-
gous for the disrupted allele.
Nephrotoxic serum nephritis (NSN). Nephrotoxic serum was pre-
pared by immunizing sheep with a particulate fraction of
mouse glomerular basement membrane from normal C57BL/6
mouse kidney (provided by H.Y. Lan, Monash Medical Centre,
Clayton, Victoria, Australia) (26). Nephrotoxic serum was
absorbed overnight against an equal volume of freshly prepared
red blood cells from B6/129 mice. The serum supernatant was
removed, heat-inactivated at 56°C for 30 min, and dialyzed
against PBS. The nephrotoxic serum was filtered (0.2 m m), and
the protein concentration was adjusted to 50 mg/ml. Control
serum was similarly prepared using pooled normal sheep
serum (Sigma Chemical Co., St. Louis, Missouri, USA).
MCP-1– intact and MCP-1–deficient male mice (8 weeks of
age, 22–25 g, n = 6) were injected subcutaneously with 1 mg of
sheep IgG mixed with CFA (1:1) (Sigma Chemical Co.). To
avoid super acute hypersensitivity caused by the administration
of sheep anti–mouse nephrotoxic serum, these mice were chal-
lenged 5 days later with intravenous injections of 50 m l (2.5 mg)
of either nephrotoxic serum or control serum for 3 consecutive
days. Mice were sacrificed on day 7.
MCP-1 transcripts. Identification of the disrupted and nondis-
rupted MCP-1 genes in experimental mice was determined by
PCR analysis. DNA was extracted from mouse tails using the
QIAmp tissue kit (QIAGEN GmbH, Hilden, Germany). The
DNA was assessed by PCR using oligonucleotide primers that
recognize either the normal MCP-1 gene (antisense R2: 5 ¢ ACA
GCT TCT TTG GGA CAC C 3 ¢ , sense F1: 5 ¢ GGA GCA TCC
ACG TGT TGG C 3¢ ) or the mutant MCP-1 gene containing the
target disruption (antisense R3: 5 ¢ ACG ATG TCG TCG TGA
CCC ATG GCG A 3 ¢ , sense F1). Gel analysis of the PCR prod-
ucts identified the normal MCP-1 gene fragment at 800 bp and
the MCP-1 mutant gene fragment at 1500 bp.
Western blot analysis of MCP-1 expression. Bone marrow
macrophages and glomeruli were extracted (27, 28) from MCP-
1–intact and –deficient mouse strains at day 7 of NSN.
Macrophages (106/ml), glomeruli (2 · 103/ml), and mesangial
cells (106/ml), were cultured in 10% FCS/DME  ± LPS (5
m g/ml) for 24 h. Culture supernatants were collected and incu-
bated overnight at 4°C with 5 m g/ml rabbit anti–mouse MCP-
1 antibody (Serotec Ltd., Oxford, United Kingdom). The super-
natant was then incubated for a further 2 h at 4°C with goat
anti–rabbit IgG conjugated to magnetic beads (BioMag;
PerSeptive Biosystems Inc., Framingham, Massachusetts,
USA). The magnetic beads were collected, washed, and incu-
bated at 95°C for 5 min in nonreducing SDS-PAGE buffer.
The samples were run on a 12% acrylamide gel. MCP-1 was
determined by Western blotting. Blots were preincubated in 5%
nonfat milk, 0.1% Tween-20, 150 mM NaCl, 50 mM Tris-HCl
(pH 7.5) to prevent nonspecific antibody binding, and then
incubated with rabbit anti–mouse MCP-1 IgG (1:5,000;
Serotec Ltd.) followed by goat anti–rabbit IgG conjugated with
horse radish peroxidase (1:10,000; Sigma Chemical Co.). The
blots were developed using ECL Supersignal reagent (Pierce
Chemical Co., Rockford, Illinois, USA), and the resulting sig-
nal was captured on Kodak X-OMAT film.
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Figure 1
Histopathology and apoptosis are reduced in renal tubules in MCP-
1(–/–) compared with MCP-1(+/+) mice given nephrotoxic serum. Cor-
tical tubular injury was extensive in MCP-1(+/+) mice receiving nephro-
toxic serum (a) (arrows; hematoxylin and PAS) but was reduced in
MCP-1(–/–) mice (b). Glomerular injury was similar in both strains.
More TEC were apoptotic in MCP-1(+/+) mice (c) compared with
MCP-1(–/–) mice (d) (TUNEL; arrows). Many F4/80+ peritubular
macrophages were detected in MCP-1(+/+) mice (e) (arrows) but were
reduced in MCP-1(–/–) mice (f). · 1000. MCP-1, monocyte chemoat-
tractant protein-1; PAS, periodic acid-Schiff; TEC, tubular epithelial
cells; TUNEL, terminal deoxynucleotide transferase–mediated dUTP
nick end-labeling.
Proteinuria. Urine protein levels in mice receiving nephro-
toxic or control serum were assessed semi-quantitively by dip-
stick analysis (Albustix; Bayer Diagnostics Division, Elkhart,
Indiana, USA) , beginning before injection and on days 1, 2, 3,
5, and 7 after the initial challenge injection.
Renal pathology. Kidney sections were fixed in 10% formalin for
24 h at 4°C. Paraffin sections (4 m m) were stained with hema-
toxylin and periodic acid-Schiff reagent (PAS). Glomerular
hypercellularity was assessed by counting the number of nucle-
ated cells in 20 glomerular cross-sections (gcs) per kidney. We
evaluated glomerular pathology by assessing 100 gcs per kidney
and determined the percentage of glomeruli with crescents
(defined as two or more cell layers within Bowman’s space) and
segmental lesions (exhibiting at least one of the following:
necrosis, proliferation, hyalinosis). The percentage of damaged
tubules (consisting of at least one of the following: dilation,
atrophy, necrosis) was determined by scoring 400 renal cortical
tubules per kidney in randomly selected microscopic fields
(400· ). All scoring was performed on blinded slides.
Antibodies. The following primary antibodies were used for
immunostaining: rat anti–mouse CD4 IgG2a clone RM4-5
(PharMingen, San Diego, California, USA) to detect CD4 T cells;
rat anti–mouse CD8a (Ly-2) IgG2a clone 53–6.7 (PharMingen)
to detect CD8 T cells; rat anti–mouse monocyte/macrophage
IgG2b clone MOMA-2 (BioSource International Inc., Camaril-
lo, California, USA) and rat anti–mouse macrophage IgG2b
(prepared from F4/80 hybridoma supernatant, ATCC No.
HB198) to detect macrophages; rabbit anti–mouse MCP-1 IgG
(Serotec Ltd.) to detect MCP-1; fluorescein-conjugated rabbit
anti–sheep IgG (Organon Teknika Corp., West Chester, Penn-
sylvania, USA) to detect sheep IgG deposits; fluorescein-conju-
gated goat anti–mouse IgG (Organon Teknika Corp.) to detect
mouse IgG deposits; fluorescein-conjugated goat anti–mouse
C3 (Organon Teknika Corp.) to detect mouse complement C3
deposits; and mouse anti-cytokeratin peptide 18 IgG1 clone CY-
90 (Sigma Chemical Co.) to detect epithelial cells. The negative
isotype control antibodies were rat IgG2a clone R35–95, rat
IgG2b clone R35–38, mouse IgG1 clone MOPC-21 (PharMin-
gen), and normal rabbit IgG (Sigma Chemical Co.). The sec-
ondary antibodies for immunostaining were biotin-conjugated
rabbit anti–rat IgG and biotin-conjugated goat anti–rabbit IgG
(Vector Laboratories, Burlingame, California, USA).
Assessment of IgG and C3 deposition in the kidney. To examine IgG
and C3 deposits in the kidney, cryostat tissue sections (4 m m)
were incubated with 20% normal goat or rabbit serum (30 min)
and then incubated with fluorescein-conjugated antibodies
detecting sheep IgG, mouse IgG, or mouse C3 (30 min). Tissue
sections were washed and mounted with VECTASHIELD (Vec-
tor Laboratories). Immunofluorescence staining was assessed by
titrating the antibodies on serial tissue sections, using twofold
dilution steps (1:100–1:25,600), and determining the dilution at
which specific staining disappears by fluorescence microscopy.
Identification of kidney-infiltrating cells by immunostaining. 
To analyze kidney-infiltrating T cells and interstitial macro-
phages, cryostat tissue sections (5 m m) were fixed in ethanol at
4°C for 10 min and immunostained with CD4, CD8, and
F4/80 antibody as described previously (27), using an avidin-
biotin-peroxidase detection system (Vector Laboratories).
Glomerular macrophages were identified in 4-m m acetone-fixed
tissue sections using MOMA-2 antibody as reported previous-
ly (29). Interstitial cell infiltration was evaluated by counting
the number of immunostained cells in the interstitium in 10
randomly selected microscopic fields (100 m m2) per kidney.
Glomerular and periglomerular cell accumulation was assessed
by counting the number of labeled cells within or adjacent to
each glomeruli, scoring 20 glomeruli at random per cross-sec-
tion. Perivascular cell accumulation was determined by semi-
quantitative scoring of cells surrounding 10 random inter- and
intralobular arteries (score: 0 = none; 1 = <2 cell layers sur-
rounding at least half the vessel; 2 = 2–5 cell layers surrounding
at least half the vessel; 3 = >5 cell layers surrounding at least half
the vessel). Peritubular cell accumulation was determined by
counting the number of labeled cells adjacent to a tubule. We
calculated the mean of 400 tubules per section selected at ran-
dom. Accumulation of macrophages and T cells within
glomeruli, adjacent to glomeruli, or adjacent to cortical tubules
was expressed as a cell index based on the number of glomeruli
and cortical tubules per section. In addition, peritubular
macrophage accumulation was correlated with the tubular
damage score obtained from the same animal.
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Figure 2
MCP-1–intact mice have nondisrupted MCP-1 DNA and express MCP-1
protein. (a) Fragments of genomic MCP-1 (800 bp) and the mutated
MCP-1 gene (1500 bp) were detected by PCR in DNA extracted from the
tails of B6/129 mice. Two samples from MCP-1–homozygous (+/+), –het-
erozygous (+/–), and –deficient (–/–) mice are represented. (b) MCP-1 pro-
tein is expressed by bone marrow macrophages (MØ), mesangial cells
(MC), and glomeruli (G) in MCP-1(+/+) mice but is absent in deficient
(–/–) mice. Cells and glomeruli were extracted at day 7 of NSN and cul-
tured for 24 h in medium alone or medium with 5 m g/ml LPS. The culture
supernatants were analyzed for the presence of MCP-1 by Western blot-
ting. NSN, nephrotoxic serum nephritis.
Figure 3
Renal transcripts of MCP-1 and MCP-3 increase in the renal cortex of
MCP-1 (+/+) mice given nephrotoxic serum. Semi-quantitative PCR
analysis was used to determine MCP-1 (black bars) and MCP-3 (gray bars)
in the renal cortex. Mice received either nephrotoxic serum (NTS), con-
trol serum (CS), or were not treated (None). Mice were sacrificed 7 days
after treatment. Mean ± SD, n = 6, *P < 0.0001. GAPDH, glyceraldehyde-
3-phosphate dehydrogenase.
Identification of MCP-1 by immunostaining. To detect MCP-1,
formalin-fixed tissue sections (5 m m) were deparaffinized and
incubated with 20% normal goat serum for 30 min. Tissue sec-
tions were then incubated with MCP-1 antibody (10 m g/ml)
in 1% BSA overnight at 4°C. Bound primary antibody was
labeled with biotin-conjugated goat anti–rabbit IgG for 1 h
and subsequently detected using the avidin-biotin-peroxidase
system (Vector Laboratories). Glomerular MCP-1 was assessed
as described for glomerular- infiltrating cells. Because MCP-
1 was not detected in medullary tubules (data not shown),
tubular MCP-1 was determined by counting the number of
cortical tubules with TEC expressing MCP-1, scoring 400
tubules per cross-section.
Identification of apoptotic cells in the kidney. Apoptotic cells in kid-
ney sections were identified by the terminal deoxynucleotide
transferase–mediated dUTP nick end-labeling (TUNEL) method
and immunoperoxidase staining (In Situ Cell Death Detection
Kit; Boehringer Mannheim Indianapolis, Indiana, USA) Apop-
tosis in TEC was assessed by counting TUNEL-labeled cells in
500 cortical tubules. TUNEL labeling and immunostaining was
scored using coded slides.
PCR assessment of renal mRNA. Total RNA was extracted
from the snap-frozen renal cortex of half a kidney using
RNAzol B (Tel-Test Inc., Friendswood, Texas, USA). A reverse
transcription (RT) reaction was performed on this RNA
using oligo-dT and the Superscript II DNA preamplification
kit (GIBCO BRL, Grand Island, New York, USA). The result-
ing RT product was used as a cDNA template for PCR analy-
sis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
expression was detected as a 500-bp product resulting from
PCR with specific oligonucleotide primers (antisense: 5¢ CAA
AGT TGT CAT GGA TGA CC 3 ¢ , sense: 5 ¢ GGT GGA GGT
CGG AGT CAA CG). Similarly, MCP-1, MCP-3, and MCP-5
expression were detected as 350-bp, 300-bp, and 550-bp PCR
products, respectively, using specific oligonucleotide primers
(MCP-1 antisense: 5 ¢ GCTTGAGGTGGTTGTGGAAAA 3 ¢ ,
MCP-1 sense: 5 ¢ CTCACCTGCTGCTACTCATTC 3 ¢ ; MCP-3
antisense: 5 ¢ CACATTCCTACAGACAGCTC 3 ¢ , MCP-3 sense:
5 ¢ AGCTACAGAAGGATCACCAG 3 ¢ ; MCP-5 antisense: 5 ¢
CTCCTTATCCAGTATGGTCC 3 ¢ , MCP-5 sense: 5 ¢ TCTC-
CTCCACCATGCAGAG 3 ¢ ).
Cell culture assays: analysis of TEC death. Bone marrow
macrophages (BMMØ) and TEC were extracted from MCP-
1–intact and –deficient mice, characterized by morphology and
antibody staining (anti-macrophage F4/80 antibody, anti-epithe-
lial cell CY-90 antibody), and grown in culture as reported previ-
ously (27, 30). We established whether MCP-1 was responsible
for inducing TEC death. MCP-1–intact and –deficient BMMØ
(106/ml) were incubated for 12–48 h in medium alone (K1 medi-
um without epidermal growth factor), or with medium contain-
ing rmMCP-1 (100 ng/ml; PharMingen) or LPS (5 m g/ml; Sigma
Chemical Co.). The supernatant from these BMMØ was collect-
ed and added (1 ml/well) to TEC (105/well) grown in 24-well
plates. TEC were cultured for 48 h with BMMØ supernatants,
media alone, or media containing rmMCP-1 or LPS. TEC necro-
sis was measured by removing cells with trypsin, staining cell sus-
pensions with 0.1% trypan blue, and counting the cells using a
hemacytometer. Samples of 150–200 cells were assessed in trip-
licate and expressed as a percentage of necrotic TEC. These exper-
iments were repeated three times using cells extracted from addi-
tional mice. TEC death by apoptosis and necrosis was
determined by staining with 1 m g/ml propidium iodide (Sigma
Chemical Co.) and annexin V (Boehringer Mannheim) as report-
ed previously (31). Apoptotic TEC were labeled with annexin V
but were impermeable to propidium iodide, whereas necrotic
TEC were stained with propidium iodide.
Statistics. Data was analyzed using the Mann-Whitney Wilcox-
on test and Spearman’s correlation coefficient.
Results
Morphological assessment of renal injury in MCP-1 intact mice
induced by NSN. Renal tubular and glomerular damage in
NSN is severe by seven days. Renal pathology was limited
to the cortex and did not involve the medulla. The major-
ity of cortical tubules (51% ± 5%) were damaged at day 7 of
NSN. Tubular damage included dilation with flattened or
degraded epithelium, atrophy, and thickening or rupture
of basement membranes (Fig. 1a). Peritubular infiltrating
cells and protein casts were also associated with most
damaged tubules. Glomerular injury was extensive (97 ±
2%) and involved at least one of the following: hyalinosis,
capillary dilation and thickening, focal segmental sclero-
sis, and crescents (Fig. 1a). Only a few glomeruli were total-
ly obliterated (<2%). We noted a prominent cell infiltrate
around most glomeruli; however, we did not detect
glomerular hypertrophy or hypercellularity.
Increased expression of monocyte chemoattractant proteins
in NSN. We verified that MCP-1–deficient mice did not
express this chemokine, because (a) we identified only
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Figure 4
MCP-1 is predominantly expressed in injured tubules in NSN. MCP-1 was
strongly expressed by most TEC but was detectable in only a few glomeru-
lar cells in MCP-1(+/+) mice at day 7 after receiving nephrotoxic serum
(a) (arrowheads); it was absent in MCP-1(–/–) mice (b).
Figure 5
Proteinuria does not decrease in MCP-1(–/–) mice given NTS. Urine pro-
tein excretion from MCP-1(+/+) mice (solid line) and MCP-1(–/–) mice
(dotted line) was measured after the administration of either NTS (filled
symbols) or control serum (unfilled symbols), and scored on a semi-quanti-
tative scale. Mean ± SD, n = 6, MCP-1(+/+) vs. MCP-1(–/–) mice (P >
0.2). NTS, nephrotoxic serum.
the disrupted MCP-1 gene in the genomic DNA of
MCP-1–deficient mice using PCR, whereas MCP-
1–intact mice had at least one allele of the nondis-
rupted MCP-1 gene (Fig. 2a), and (b) MCP-1 was not
detected in lipopolysaccharide (LPS)-stimulated
BMMØ and RPC supernatants from MCP-1–deficient
mice compared with MCP-1–intact mice using West-
ern blot analysis (Fig. 2b).
MCP-1 was upregulated in the kidney in NSN. There
was an increase in MCP-1 transcripts (four- to fivefold)
in the renal cortex of MCP-1–intact mice at day 7 of
NSN compared with MCP-1–intact mice receiving con-
trol sera or uninjected controls (Fig. 3). MCP-1 was
identified predominantly in cortical tubules (>90%) in
mice with NSN by immunostaining (Fig. 4a). Lesser
amounts of MCP-1 were expressed in glomerular cres-
cents, parietal epithelial cells, and a small proportion of
cells (10%) within the glomerular tuft (4.2 ± 0.3
cells/gcs) during NSN. Thus, MCP-1 expression in TEC
far exceeds the amount within glomeruli.
Because MCP-3 and MCP-5 are also ligands for the
MCP-1 receptor (CCR2), we examined whether kidney
expression of these molecules is upregulated following
renal injury. Constitutive mRNA expression of MCP-3
increased three- to fourfold in MCP-1–intact and –defi-
cient mice with NSN as measured by RT-PCR (Fig. 3). In
contrast, MCP-5 was not detected in the kidney of MCP-
1–intact or –deficient strains. We ensured that MCP-3
and MCP-5 could be detected by establishing the pres-
ence of these molecules in the spleens of MCP-1–intact
and –deficient mice (data not shown).
The absence of MCP-1 does not prevent IgG/C3 deposition
and proteinuria in NSN. Sheep IgG, mouse IgG, and com-
plement C3 were prominent on the glomerular base-
ment membrane in mice that received nephrotoxic
serum. The localization and level of IgG (sheep and
mouse) and C3 deposition was not different in MCP-
1–intact and –deficient mice, as determined by antibody
titration (data not shown).
We did not detect any difference in the incidence or
severity of proteinuria in MCP-1–intact and –deficient
mice receiving nephrotoxic serum (Fig. 5). MCP-1–intact
mice given nephrotoxic serum became rapidly protein-
uric. Proteinuria was evident at day 1 of disease and
peaked at day 3; it remained elevated until the mice were
sacrificed on day 7 after receiving nephrotoxic serum. By
comparison, MCP-1–intact and –deficient mice receiving
control sera remained nonproteinuric.
The absence of MCP-1 protects from damage to tubules, but
not glomeruli, in NSN. We detected fewer damaged cor-
tical tubules in MCP-1–deficient compared with MCP-
1–intact strains with NSN using histopathologic cri-
teria (Fig. 6a and Fig. 1, a and b). This was associated
with a reduction in the percentage of apoptotic
tubules (Fig. 6b and Fig. 1, c and d). In contrast, MCP-
1–deficient glomeruli were not protected from renal
injury. There was no difference in the number of dam-
aged glomeruli (97 ± 2%), the severity of damage, or
crescent formation (12 ± 2%) in the MCP-1–intact and
–deficient strains with NSN.
The absence of MCP-1 reduces the accumulation of
macrophages in the interstitium in NSN. F4/80 antibody
detected macrophages in periglomerular, peritubular,
and perivascular lesions but did not stain for the presence
of macrophages within glomeruli in MCP-1–intact and
–deficient mice. In contrast, MOMA-2 antibody detected
macrophages within glomeruli and labeled fewer
macrophages in the interstitium compared with F4/80.
Therefore, we analyzed macrophages in the interstitium
and glomeruli with F4/80 antibody and MOMA-2 anti-
body, respectively.
At day 7 of NSN, the number of peritubular macro-
phages correlated with the extent of damage in cortical
tubules (r = 0.93, P < 0.0001, n = 12) in MCP-1–intact and
–deficient mice. There were fewer macrophages in the
interstitium and adjacent to damaged tubules in MCP-1–
deficient kidneys compared with MCP-1–intact kidneys
(Fig.7 and Fig. 1, e and f ). In contrast, we detected no dif-
ference in the number of macrophages within glomeruli
(Fig. 7), nor in the glomerular cell number (40 ± 4 cells
MCP-1(+/+) vs. 43 ± 2 cells MCP-1(–/–), P = 0.2) in MCP-
1–intact and –deficient mice.
Infiltrating CD4+ and CD8+ T cells were seen mainly in
perivascular areas but were also seen adjacent to
glomeruli and tubules, and within glomeruli (Fig. 7).
There was no difference in T-cell accumulation in MCP-
1–intact and –deficient strains (Fig. 7; perivascular CD4
cell score: 0.9 ± 0.3 MCP-1(+/+) vs. 0.8 ± 0.2 MCP-1(–/–),
P = 0.2; perivascular CD8 cell score: 0.3 ± 0.2 MCP-1(+/+)
vs. 0.2 ± 0.2 MCP-1(–/–), P = 0.3).
MCP-1 does not induce TEC death. Because tubule dam-
age is reduced in MCP-1–deficient mice given nephro-
toxic serum, we examined whether MCP-1 induced TEC
death. rMCP-1 (100 ng/ml) did not reduce the viability
of MCP-1–intact or –deficient TEC in culture (Fig. 8).
Therefore, MCP-1 does not directly destroy TEC.
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Figure 6
Reduced renal tubule damage in MCP-1(–/–) mice given nephro-
toxic serum. Tubule injury was assessed at day 7 of NSN by (a)
histology (hematoxylin and PAS) and (b) TUNEL labeling of apop-
totic TEC. Tubules (400) were scored in the renal cortex in ran-
domly selected fields ( · 400). Black bars represent MCP-1(+/+)
and gray bars represent MCP-1(–/–) mice. Mean ± SD, n = 6, *P
< 0.05, **P < 0.0005.
Macrophages release molecules that induce TEC apoptosis. To
test the hypothesis that activated macrophages induce
TEC damage, we incubated TEC with supernatant derived
from activated BMMØ. Supernatant from LPS-stimulated
BMMØ induced greater TEC death (16%–24%) compared
with unstimulated BMMØ (5%–7%), whereas TEC death
induced by MCP-1–stimulated BMMØ did not differ from
unstimulated BMMØ (Fig. 8). TEC death was not depend-
ent on whether BMMØ or TEC were derived from MCP-
1–intact or –deficient mice, and LPS was not directly toxic
to TEC. Furthermore, coculture of BMMØ with TEC in
the presence of LPS induced TEC death similar to BMMØ
supernatant alone (data not shown). We determined that
macrophage-mediated TEC cell death was in part due to
apoptosis, because a proportion of TEC (18% ± 5%) that
were not necrotic (TEC impermeable to propidium iodide)
stained with the apoptosis marker, annexin V, after treat-
ment with LPS-stimulated BMMØ supernatant.
Discussion
In this report, we tested the hypothesis that MCP-1 is
required for tubular or glomerular damage in an
induced model of renal injury, NSN. We report that in
NSN, MCP-1 increases predominantly in TEC in the kid-
ney and is sparse within glomeruli. Furthermore,
macrophage accumulation adjacent to TEC correlates
with tubular damage and increased tubular MCP-1
expression. We conclude that MCP-1 recruits
macrophages that are already activated, or become acti-
vated within the kidney, and release molecules responsi-
ble for TEC death.
The correlation of peritubular macrophages, MCP-1
expression on TEC, and tubular damage suggests that
MCP-1–mediated tubule damage is dependent on
macrophages. This concept is supported by our findings
that (a) macrophage accumulation adjacent to tubules
in NSN is reduced in MCP-1–deficient mice, and (b)
activated BMMØ release molecules that cause TEC
death. Our findings also suggest that MCP-1 recruits,
but does not stimulate, macrophages to release mole-
cules that induce TEC death. This is consistent with
reports that transgenic mice expressing MCP-1 in alve-
olar epithelial cells or pancreatic islet cells induce local
macrophage accumulation but require an additional
signal (LPS) for inflammation to ensue (32, 33). In our
study, we established that MCP-1 does not induce
macrophages to release molecules toxic to tubules. It
will be important to determine whether macrophages
recruited by MCP-1 expressed on TEC are stimulated to
become nephrotoxic within the kidney.
TEC death is not exclusively dependent on MCP-
1–recruited macrophages. In the absence of MCP-1,
macrophage accumulation and tubular damage are
reduced, but not eliminated, in NSN. In addition,
although MCP-1 is induced in TEC in another model of
kidney injury, unilateral ureteral ligation (UUL), MCP-
1–deficient kidneys are not protected from an influx of
macrophages or tubular damage (our unpublished find-
ings) One possible explanation is that the mechanical
induction of tubular damage in UUL induces an array of
additional molecules that are responsible for recruiting
macrophages. Thus, MCP-1 is made redundant by other
macrophage-recruiting molecules. By comparison,
although immune-mediated renal injury in NSN is not
entirely dependent on MCP-1 to recruit macrophages,
MCP-1 is responsible for a large proportion (40%) of
these tubular damaging cells.
There are several reasons that would explain why the
glomerular injury was not protected in the absence of
MCP-1 in NSN. First, renal injury may require a thresh-
old of MCP-1 that was not reached in glomeruli. Corti-
cal TEC expression of MCP-1 is abundant in MCP-
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Figure 7
Peritubular macrophages, but not T cells or glomerular macrophages, are
reduced in MCP-1(–/–) mice given nephrotoxic serum. Intrarenal
macrophages and T cells were assessed in MCP-1(+/+) and MCP-1(–/–)
mice 7 days after receiving nephrotoxic serum. Macrophages were detect-
ed with F4/80 antibody (interstitium, periglomerular) and MOMA-2 anti-
body (intraglomerular). Interstitial and glomerular T cells were detected
using CD4 and CD8 antibodies (scoring: periglomerular cells/glomerular
cross-section (gcs); peritubular cells/tubule cross-section; intraglomeru-
lar cells/gcs). Mean ± SD, n = 6, *P < 0.005 compared with MCP-1(+/+).
Figure 8
TEC are injured by MØSN. TEC were cultured in medium with and with-
out stimuli (gray bars), or in the presence of MØSN (black bars). TEC from
MCP-1(+/+) mice were cultured with MØSN from MCP-1(+/+) mice.
After incubation, cells were briefly trypsinized and stained with 0.1% try-
pan blue. The percentage of necrotic TEC was determined by counting
trypan blue–stained cells. Results are based on the mean values from
three experiments. Similar results were obtained using TEC and MØSN
from MCP-1 (–/–) mice (data not shown). Mean ± SD, n = 3,*P < 0.01,
**P < 0.005. MØSN, macrophage supernatant.
1–intact mice with NSN, whereas glomerular expression
is sparse. Thus, it is not surprising that the impact of
removing MCP-1 from glomeruli is negligible. Second,
glomerular deposition of IgG and C3 was the same in
MCP-1–intact and –deficient mice that received nephro-
toxic serum. Therefore, the recruitment of glomerular
macrophages via Fc- and C3-dependent mechanisms is
unlikely to be different in MCP-1–deficient mice with
NSN. Third, macrophages recruited to the tubules and
glomeruli by MCP-1 may differ. We noted that the
macrophages in the interstitium and glomeruli
expressed different antigenic markers (34). These
macrophage antigen markers may reflect distinct states
of maturation, and in turn, responsiveness to MCP-1
recruitment. Fourth, chemokines other than MCP-1
released by glomerular cells during NSN may be respon-
sible for recruiting of macrophages. Glomeruli isolated
from rats with NSN have an increase in CC chemokine
transcripts that attract macrophages, including
macrophage inflammatory protein (MIP)-1 a , MIP-1 b ,
RANTES, TCA3, and MCP-3 (35). Furthermore, other
CC chemokines associated with macrophage-dependent
inflammation, including MCP-2, MCP-4, I309, and
hemofiltrate CC. chemokine(HCC)-1 (3), may be re-
leased during glomerular injury. To add to this com-
plexity, there are at least three monocyte CC chemokine
receptors (CCR1, CCR2, and CCR5) (3). MCP-1 attracts
macrophages by signaling through the CCR2 chemokine
receptor, and in addition to MCP-1, MCP-3 and MCP-5
are coligands for this receptor (36, 37). Therefore,
because intrarenal MCP-3, but not MCP-5, transcripts
increase in MCP-1–intact and –deficient mice with NSN,
MCP-3 may compensate for the lack of glomerular MCP-
1 signaling through CCR2. In addition, it is possible that
B6/129 hybrids have undergone sorting for an allele(s)
that provides protection against renal injury. However,
this is unlikely because the extent of tubular damage cor-
related with the influx of macrophages adjacent to
tubules. Clearly, the differential impact of MCP-1 on
tubule, but not glomerular, injury has begotten a series
of questions that will be instrumental in our under-
standing of the pathogenesis of kidney disease.
Genetic deletion of MCP-1 and blockade of MCP-1 via
antibodies have a differing impact on kidney injury in
NSN. Provision of MCP-1 antibody reduces glomerular
injury in NSN (29, 38–40). In contrast, MCP-1–deficient
mice given nephrotoxic serum were not protected from
glomerular damage. These differences may be related to
the amount, location, and period in which MCP-1 is
eliminated during the development of renal disease. This
is not surprising. In addition, there are numerous exam-
ples highlighting the differences between genetic target-
ed disruption and antibody strategies that target mole-
cules promoting inflammation to thwart the
progression of immune-mediated diseases (41–43). It is
also worth noting that the differences in NSN are
dependent on the preparation of nephrotoxic serum and
on the animal strain. In fact, there is varying efficacy
using anti–MCP-1 antibody in NSN; while Lloyd et al.
provide evidence of glomerular protection at day 7 (29),
another report claims that protection is transient and is
lost after day 3 (40). These findings underscore the com-
plexity of designing therapeutic strategies for eliminat-
ing MCP-1 to combat human kidney disease.
In conclusion, our data suggest that strategies that
eliminate MCP-1 would protect against progressive loss
of tubules in patients with tubulointerstitial kidney dis-
eases. We are currently investigating the impact of elim-
inating MCP-1 in MRL-Faslpr mice that spontaneously
develop glomerular and tubular injury closely resem-
bling human lupus nephritis.
Acknowledgments
We wish to thank Clare M. Lloyd (Millenium Pharmaceuticals,
Cambridge, Massacusetts, USA) for editorial assistance in the
preparation of this manuscript. This work was supported in
part by a National Kidney Foundation Fellowship Grant to
G.H. Tesch, the Polycystic Kidney Research Foundation and
the National Institute of Health and Grant DK 36149.
1. Paterson, D.J., Lan, H.Y., and Atkins, R.C. 1997. Macrophages in immune
renal injury. In Immunologic renal disease. E.G. Neilson and W.G. Couser,
editors. Raven Press. New York, NY. 575–592.
2. Rovin, B.H., and Phan, L.T. 1998. Chemotactic factors and renal inflam-
mation. Am. J. Kidney Dis. 31:1065–1084.
3. Rollins, B.J. 1997. Chemokines. Blood. 90:909–928.
4. Cook, D.N., et al. 1995. Requirement for MIP-1 a for an inflammatory
response to viral infection. Science. 269:1583–1585.
5. Lu, B., et al. 1998. Abnormalities in monocyte recruitment and cytokine
expression in MCP-1 deficient mice. J. Exp. Med. 187:601–608.
6. Valente, A.J., Graves, D.T., Vialle-Valentin, C.E., Delgado, R., and
Schwartz, C.J. 1988. Purification of monocyte chemotactic factor secret-
ed by nonhuman primate vascular cells in culture. Biochemistry.
27:4162–4168.
7. Carr, M.W., Roth, S.J., Luther, E., Rose, S.S., and Springer, T.A. 1994.
Monocyte chemoattractant protein-1 acts as a T-lymphocyte chemoat-
tractant. Proc. Natl. Acad. Sci. USA. 91:3652–3656.
8. Allavena, P., et al. 1994. Induction of natural killer cell migration by
monocyte chemotactic protein-1, -2 and -3. Eur. J. Immunol.
24:3233–3236.
9. Rovin, B.H., Rumancik, M., Tan, L., and Dickerson, J. 1994. Glomerular
expression of monocyte chemoattractant protein-1 in experimental and
human glomerulonephritis. Lab. Invest. 71: 536–542.
10. Prodjosudjadi, W., et al. 1995. Production and cytokine-mediated regu-
lation of monocyte chemoattractant protein-1 by human proximal tubu-
lar epithelial cells. Kidney Int. 48:1477–1486.
11. Wada, T., et al. 1996. Monitoring urinary levels of monocyte chemotac-
tic and activating factor reflects disease activity of lupus nephritis. Kid-
ney Int. 49:761–767.
12. Grandaliano, G., et al. 1996. Monocyte chemotactic peptide-1 expression
in acute and chronic human nephritides: a pathogenetic role in inter-
stitial monocytes recruitment. J. Am. Soc. Nephrol. 7:906–913.
13. Rovin, B.H., Yoshiumura, T., and Tan, L. 1992. Cytokine-induced pro-
duction of monocyte chemoattractant protein-1 by cultured human
mesangial cells. J. Immunol. 148:2148–2153.
14. Hora, K., et al. 1992. Receptors for IgG complexes activate synthesis of
monocyte chemoattractant peptide 1 and colony-stimulating factor 1.
Proc. Natl. Acad. Sci. USA. 89:1745–1749.
15. Schmouder, R.L., Strieter, R.M., and Kunkel, S.L. 1993. Interferon-
gamma regulation of human renal cortical epithelial cell-derived mono-
cyte chemotatic peptide-1. Kidney Int. 44:43–49.
16. Stahl, R.A., et al. 1993. Increased expression of monocyte chemoattrac-
tant protein-1 in anti-thymocyte antibody-induced glomerulonephritis.
Kidney Int. 44:1036–1047.
17. Safirstein, R., et al. 1991. Expression of cytokine-like genes JE and KC is
increased during renal ischemia. Am. J. Physiol. 261:F1095–F1101.
18. Diamond, J.R., Kees-Folts, D., Ding, G., Frye, J.E., and Restrepo, N.C.
1994. Macrophages, monocyte chemoattractant peptide-1, and TGF- b 1
in experimental hydronephrosis. Am. J. Physiol. 266:F926–F933.
19. Eddy, A.A., and Giachelli, C.M. 1995. Renal expression of genes that pro-
mote interstitial inflammation and fibrosis in rats with protein-overload
proteinuria. Kidney Int. 47:1546–1557.
20. Pichler, R., et al. 1994. Tubulointerstitial disease in glomerulonephritis.
Potential role of osteopontin (uropontin). Am. J. Pathol. 144:915–926.
21. Deckers, J.G., Van der Woude, F.J., Van der Kooij, S.W., and Daha, M.R.
1998. Synergistic effect of IL-1-alpha, IFN-gamma and TNF-alpha on
RANTES production by human renal tubular epithelial cells in vitro. J.
Am. Soc. Nephrol. 9:194–202.
22. Rovin, B.H., Doe, N., and Tan, L.C. 1996. Monocyte chemoattractant
The Journal of Clinical Investigation | January 1999 | Volume 103 | Number 1 79
protein-1 levels in patients with glomerular disease. Am. J. Kidney Dis.
27:640–646.
23. Boring, L., et al. 1997. Impaired monocyte migration and reduced type 1
(Th1) cytokine responses in C-C chemokine receptor 2 knockout mice.
J. Clin. Invest. 100:2552–2561.
24. Kurihara, T., Warr, G., Loy, J., and Bravo, R. 1997. Defects in macrophage
recruitment and host defense in mice lacking the CCR2 chemokine
receptor. J. Exp. Med. 186:1757–1762.
25. Kuziel, W.A., et al. 1997. Severe reduction in leukocyte adhesion and
monocyte extravasation in mice deficient in CC chemokine receptor 2.
Proc. Natl. Acad. Sci. USA. 94:12053–12058.
26. Tipping, P.G., Huang, X.R., Berndt, M.C., and Holdsworth, S.R. 1994. A
role for P-selectin in complement-independent neutrophil-mediated
glomerular injury. Kidney Int. 46:79–88.
27. Moore, K.J., Naito, T., Martin, C., and Kelley, V.R. 1996. Enhanced
response of macrophages to CSF-1 in autoimmune mice. A gene trans-
fer strategy. J. Immunol. 157:433–440.
28. Bloom, R.D., Florquin, S., and Kelley, V.R. 1993. Colony stimulating fac-
tor-1 in the induction of lupus nephritis. Kidney Int. 43:1000–1009.
29. Lloyd, C.M., et al. 1997. RANTES and monocyte chemoattractant pro-
tein-1 (MCP-1) play an important role in the inflammatory phase of
crescentic nephritis, but only MCP-1 is involved in crescent formation
and interstitial fibrosis. J. Exp. Med. 185:1371–1380.
30. Wuthrich, R.P., et al. 1990. MHC class II, antigen presentation and
tumour necrosis factor in renal tubular epithelial cells. Kidney Int.
37:783–792.
31. Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C.
1995. A novel assay for apoptosis. Flow cytometric detection of phos-
phatidylserine expression on early apoptotic cells using fluorescein
labelled Annexin V. J. Immunol. Methods. 194:39–51.
32. Gunn, M.D., Nelken, N.A., Liao, X., and Williams, L.T. 1997. Monocyte
chemoattractant protein-1 is sufficient for the chemotaxis of monocytes
and lymphocytes in transgenic mice but requires an additional stimulus
for inflammatory activation. J. Immunol. 158:376–383.
33. Grewal, I.S., et al. 1997. Transgenic monocyte chemoattractant protein-
1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without
diabetes: abrogation by a second transgene expressing systemic MCP-1.
J. Immunol. 159:401–408.
34. Leenen, P.J., De Bruijn, M.F., Voerman, J.S., Campbell, P.A., and Van
Ewijk, W. 1994. Markers of mouse macrophage development detected
by monoclonal antibodies. J. Immunol. Methods. 174:5–19.
35. Natori, Y., Sekiguchi, M., Ou, Z., and Natori, Y. 1997. Gene expression of
CC chemokines in experimental crescentic glomerulonephritis (CGN).
Clin. Exp. Immunol. 109:143–148.
36. Franci, C., Wong, L.M., Van, D.J. Proost, P., and Charo, I.F. 1995. Mono-
cyte chemoattractant protein-3, but not monocyte chemoattractant pro-
tein-2, is a functional ligand of the human monocyte chemoattractant
protein-1 receptor. J. Immunol. 154:6511–6517.
37. Sarafi, M.N., Garcia-Zepeda, E.A., MacLean, J.A., Charo, I.F., and Luster,
A.D. 1997. Murine monocyte chemoattractant protein (MCP)-5: a novel
CC chemokine that is a structural and functional homologue of human
MCP-1. J. Exp. Med. 185:99–109.
38. Tang, W.W., Qi, M., and Warren, J.S. 1996. Monocyte chemoattractant
protein-1 mediates glomerular macrophage infiltration in anti-GBM Ab
GN. Kidney Int. 50:665–671.
39. Wada, T., et al. 1996. Intervention of crescentic glomerulonephritis by
antibodies to monocyte chemotactic and activating factor (MCAF/MCP-
1). FASEB. J. 10:1418–1425.
40. Fujinaka, H,. et al. 1997. Suppression of anti-glomerular basement
membrane nephritis by administration of anti-monocyte chemoattrac-
tant protein-1 antibody in WKY rats. J. Am. Soc. Nephrol. 8:1174–1178.
41. Doerschuk, C.M., et al. 1996. The role of P-selectin and ICAM-1 in acute
lung injury as determined using blocking antibodies and mutant mice.
J. Immunol. 157:4609–4614.
42. Ma, J., et al. 1996. Autoimmune lpr/lpr mice deficient in CD40 ligand:
spontaneous Ig class switching with dichotomy of autoantibody
responses. J. Immunol. 157:417–426.
43. Early, G.S., Zhao, W., and Burns, C.M. 1996. Anti-CD40 ligand antibody
treatment prevents the development of lupus-like nephritis in a subset
of New Zealand black x New Zealand white mice. Response correlates
with the absence of an anti-antibody response. J. Immunol.
157:3159–3164. 
80 The Journal of Clinical Investigation | January 1999 | Volume 103 | Number 1
